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Summary The aims ofthis study are to
describe the adequacyof treatment for
anxiety and depressive disorders in
Europe andhowitdiffers between
providers, usingdata fromthe ESEMeD
study. The overallproportion of adequate
treatmentwas 45.8% (57.4% inthe
specialised sector and 23.3% inthe
generalmedical care sector).Between-
countrydifferenceswere found in
treatment adequacy inthe specialised
setting.Organisational andpolitical
aspectsmayexplainthese findings.
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Research on quality of care for mental dis-
orders has systematically reported low rates
of treatment guideline adherence (Ramana
et al, 1999; McConnell et al, 2002; Oquendo
et al, 2002; Kessler et al, 2003; Wang et al,
2005). This has significant health conse-
quences, since treatments meeting clinical
guidelines are cost-effective and decrease
years lived with disability (Andrews et al,
2004). The majority of previous studies have
been conducted in the USA, and little is
known about treatment adequacy in Europe.
This study is based on a European epide-
miological study of the prevalence and treat-
ment of mental disorders. Our aims are to
describe treatment adequacy for anxiety and
depressive disorders in Europe, how it differs
between countries and providers, and which
factors are associated with appropriate care.
METHOD
The European Study of the Epidemiology of
Mental Disorders (ESEMeD) project is a
cross-sectional household survey represen-
tative of the non-institutionalised adults of
Belgium, France, Germany, Italy, The
Netherlands and Spain. A stratified, multi-
stage, clustered area, probability sample
without replacement design was used. Data
for the project were provided by 21 425
respondents. A description of the ESEMeD
methodology has been provided by Alonso
et al (2004). Response rates ranged from
45.9% in France to 78.6% in Spain.
Mental health status was assessed with
the Composite International Diagnostic Inter-
view 3.0 (Kessler & Ustun, 2004). The
diagnoses included in this paper were DSM–
IV major depressive episode and anxiety dis-
orders (social phobia, generalised anxiety dis-
order and panic disorder) (American
Psychiatric Association, 1994). Individuals
reporting any use of health services as a result
of their ‘emotions or mental health problems’
in the 12 months before the interview were
asked to select whom they visited from a list
including psychiatrist, psychologist, general
practitioner (GP) or any other medical doctor.
Psychiatrists and psychologists constituted
the specialised mental health category;
GPs and other doctors formed the general
medical care category.
Criteria for minimally adequate treat-
ment were receiving antidepressant pharma-
cotherapy (for depression) or antidepressant
or anxiolytic pharmacotherapy (for anxiety)
for at least 2 months plus at least four visits
with a psychiatrist, a GP or any other doctor;
or at least eight sessions with a psychologist
or a psychiatrist lasting an average of 30 min
(American Psychiatric Association, 1998,
2000; Guidelines Advisory Committee,
2001; Kessler et al, 2003; Royal Australian
and New Zealand College of Psychiatrists,
2003; National Institute for Clinical Excel-
lence, 2004; Wang et al, 2005).
Data were weighted to adjust for the
multistage probability sampling. Popu-
lation projection weights were used to re-
store the representativeness of the sample
regarding age and gender distribution in
each country. A logistic model was used to
analyse factors associated with treatment ade-
quacy. Since the same individual could have
received treatment in both the specialised
and general medical sectors, a generalised es-
timating equation model was used, including
two observations for those treated in both sec-
tors (Zeger & Liang, 1986). Statistical ana-
lyses were carried out using Stata version
8.0 and SAS veresion 9.1 for Windows.
RESULTS
An average of 29.5% (429 individuals) of
those with a diagnosis of major depressive
episode or anxiety disorder in the past 12
months had consulted any health service dur-
ing that period. Of these individuals, 59 lived
in Belgium, 89 in France, 49 in Germany, 36
in Italy, 62 in The Netherlands and 134 in
Spain. The overall proportion of treatment
adequacy for any disorder was 45.8%
(95% CI 39.2–52.4), ranging between
45.8% (95% CI 38.47–53.05) for major de-
pressive episode and 54.5% (95% CI 44.78–
64.19) for anxiety disorder. By setting, rate
of treatment adequacy for any disorder was
57.4% (95% CI 49.7–65.1) in the specialised
care category and 23.3% (95% CI 16.7–
29.8) in the general medical care category
(specialised care as reference, OR¼0.25,
95% CI 0.16–0.38). The same pattern was
observed for both types of disorder.
By country, overall proportions of
adequacy varied from 32.5% (95% CI
21.5–43.2) in Spain to 55.4% (95% CI
40.3–70.5) in The Netherlands (P¼0.11).
The proportion of individuals receiving
minimally adequate treatment in the
specialised care varied widely, from
29.2% (95% CI 17.4–41.0) in Spain to
78.2% (95% CI 65.4–91.0) in France
(P50.001). In the general medical setting,
proportions varied between 14.9% (95%
CI 1.0–28.7) in Belgium and 33.6% (95%
CI 14.4–52.9) in Italy (P¼0.54).
Being treated by a general medical pro-
vider was associated with a lower probabil-
ity of receiving adequate treatment in
Belgium (OR¼0.24, 95% CI 0.19–0.64),
France (OR¼0.09, 95% CI 0.04–0.23),
Germany (OR¼0.16, 95% CI 0.05–0.56)
and The Netherlands (OR¼0.35, 95% CI
0.18–0.69). Provider differences in each
country according to disorder were similar
to the overall differences.
Two different models were run in order to
ascertain the factors associated to treatment
adequacy. After adjusting by gender, age
(centralised around median value, 42 years
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old), urbanicity (living in a city with
4100,000 inhabitants v. smaller), presence
or absence of chronic illness, and health state
assessed using the EuroQol, only type of pro-
vider and country were related to treatment
adequacy. As some interaction between pro-
vider and country was detected, we adjusted
a second model. In this model, provider by
itself was not significant (taking specialised
care as reference, OR¼0.76, 95% CI 0.34–
1.71). Using Spain as reference, living in
France (OR¼8.91, 95% CI 3.37–23.55),
Germany (OR¼5.16, 95% CI 1.81–14.18)
and The Netherlands (OR¼5.14, 95% CI
1.94–13.62) was related to increased prob-
ability of receiving adequate treatment. Only
the interactions between provider (general-
ised care) and France (OR¼0.10, 95% CI
0.03–0.35) or Germany (OR¼0.20, 95%
CI 0.05–0.84) were statistically significant.
(The results are summarised in a data supple-
ment to the online version of this paper.)
DISCUSSION
Results should be interpreted considering the
following limitations. First, information about
treatment was self-reported. Second, the final
sample considered was small and data should
be interpreted with caution. Third, we have
not been able to analyse how national differ-
ences in response rateaffect the results. Finally,
we might have underestimated treatment in-
adequacy owing to the loose criteria used .
In spite of the limitations, our results
suggest that treatment adequacy rates for
anxiety disorders and major depressive
episodes in Belgium, France, Germany, Italy,
The Netherlands, and Spain are similar to
those found by Wang et al (2005) in the
USA. Rates of minimal adequate treatment
in the USA were 52.0% in the specialised set-
ting and 14.9% in the general medical set-
ting; in Europe the rates were 57.4% and
23% respectively. However, Wang’s study
included all DSM–IV diagnoses, whereas
we focused on only two types of disorder.
Although overall rates of adequacy
were similar across Europe, the differences
between providers varied. In the northern
countries (Belgium, France, Germany and
The Netherlands) treatment adequacy was
higher in the specialised sector, whereas in
the southern countries (Italy and Spain)
there was no difference. This result was
not anticipated, since published studies
systematically report that those treated in
a specialised setting are more likely to re-
ceive adequate treatment (Knieser et al,
2005; Wang et al, 2005).
Differences in European healthcare sys-
tems might explain these variations. Spain
and Italy have a national health service
financed by general taxation; the other
countries have a system of compulsory so-
cial health insurance. In Spain and Italy a
GP referral is usually needed to access spe-
cialised care. Practice guidelines could also
explain differences. Practice guidelines
have, at least theoretically, an important
role in France, Germany and The Nether-
lands. In France, the National Agency for
Accreditation and Evaluation of Health
Care has published a depression guideline;
Germany has an Institute for Quality and
Efficiency that promotes evidence-based
treatments; and in The Netherlands both
GPs and psychiatrists publish guidelines
for depression (more information on the
healthcare systems of these countries can be
obtained from the European Observatory,
http://www.euro.who.int/observatory). How-
ever, the role of practice guidelines has been
questioned by Gilbody et al (2003), who
highlight the point that simple guideline
creation is ineffective. The finding that
France and Germany have a high overall
adequacy rate but low adequacy in the
general medical setting, whereas The
Netherlands has one of the highest rates of
treatment adequacy in the general medical
setting, could be explained by the fact that
guidelines in The Netherlands were devel-
oped by both primary care physicians and
specialists, supporting the hypothesis that
collaborative care improves quality of care.
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